Adomiparin

Drug Profile

Adomiparin

Alternative Names: M118

Latest Information Update: 29 Jul 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Momenta Pharmaceuticals
  • Class Antithrombotics; Low molecular weight heparins
  • Mechanism of Action Antithrombin III inhibitors; Factor Xa inhibitors; Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute coronary syndromes

Most Recent Events

  • 10 Mar 2011 Adomiparin is available for partnering (http://http://www.momentapharma.com/index.html)
  • 02 Nov 2010 Momenta Pharmaceuticals receives a Qualifying Therapeutic Discovery Project grant from the US Government for M 118 development in Acute coronary syndromes
  • 24 Sep 2009 Efficacy and adverse events data from the phase IIa EMINENCE trial released by Momenta Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top